

August 12, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl.: As above

Press Release

Investor Relations | Corporate Communications
Phone: 040-66725401 / 66725000
Email: ir@aurobindo.com

Hyderabad, India, August 12th, 2023: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended June 30, 2023.

Aurobindo Pharma Ltd. Q1FY24 Consolidated Financial Results

Amount (INR Cr)	Q1FY24	Q1FY23	% Change YoY	Q4FY23	% Change QoQ
Revenue from operations	6,850.5	6,235.9	9.9%	6,473.0	5.8%
EBITDA before Forex and Other Income	1,151.4	964.7	19.3%	1002.2	14.9%
EBITDA margin (%)	16.8%	15.5%	134 bps	15.5%	132 bps
EBITDA before R&D	1,539.0	1,274.8	20.7%	1,412.9	8.9%
EBITDA margin before R&D (%)	22.5%	20.4%	202 bps	21.8%	64 bps
PBT before share of P/L of JV, Forex, and Exceptional items	846.9	711.2	19.1%	713.3	18.7%
Net Profit after Share of Profit/Loss of JV and minority interest	570.8	520.5	9.7%	505.9	12.8%

Key highlights of Q1FY24

- Revenue from Operations at INR 6,850.5 Cr increased by 9.9% YoY
- US formulations revenue increased by 11.2% YoY to INR 3,304 Cr
- Europe formulation revenue stood at INR 1,837 Cr, with an increase of 18.6% YoY
- Growth Markets revenue grew by 12.9% YoY to INR 486 Cr
- ARV revenue stood at INR 190 Cr
- API revenue grew by 14.0% YoY to INR 1,033 Cr
- EBITDA before Forex and Other income stood at INR 1,151.4 Cr; EBITDA margin for the quarter was 16.8%.
- Research & Development (R&D) spend at INR 387.6 Cr, 5.7% of revenues (Q4 FY23: 6.3%)
- Received final approval for 19 ANDAs including 7 injectable products from the USFDA
- Net Profit after Share of Profit/Loss of JV and minority interest stood at INR 570.8 Cr, as against INR 520.5 Cr in Q1FY23
- Basic & Diluted EPS is INR 9.74 per share.

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased to start the new financial year on a good note with strong top-line growth and margin expansion aided by improved performance across our key markets. With our product pipeline continuing to advance, and execution of growth drivers proceeding as planned, we are confident that our fundamental strengths position us to create an upward trajectory. Looking ahead, we are confident in executing our growth initiatives and creating long-term value for our shareholders."



Operational Performance (Consolidated)

Amount (INR Cr)	Q1FY24	Q1FY23	% Change YoY	Q4FY23	% Change QoQ
Formulations					
USA	3,304	2,971	11.2%	3,045	8.5%
Europe	1,837	1,548	18.6%	1,660	10.6%
Growth Markets*	486	431	12.9%	592	-17.9%
ARV	190	380	-49.9%	159	19.6%
Total Formulations	5,817	5,329	9.2%	5,456	6.6%
Active Pharmaceutical Ingredients (API)					
Betalactam	719	551	30.4%	638	12.8%
Non Betalactam	314	355	-11.5%	380	-17.3%
Total API	1,033	907	14.0%	1,017	1.6%
Consolidated Gross Sales (incl. service income)	6,851	6,236	9.9%	6,473	5.8%
Dossier Income	0	0	-	0	-
Revenue from operations	6,851	6,236	9.9%	6,473	5.8%

*includes domestic formulation sales of INR 52.4 Cr in Q1 FY24

Q1FY24: Consolidated revenue breakup - Geography & Segment wise

Q1FY24



Formulations

For the quarter, Formulation revenue increased by 9.2% YoY to INR 5,817 Cr

US Formulations

- In Q1 FY24, US revenue increased by 11.2% YoY to INR 3,304 Cr and accounted for 48.2% of consolidated revenues.
- Filed 12 ANDAs including 1 Injectable product with USFDA in Q1 FY24
- Received final approval for 19 ANDAs including 7 injectable products in Q1 FY24
- As on 30th June 2023, on a cumulative basis, the company has filed 814 ANDAs with USFDA and received 613 final approval and 34 tentative approval
- The company has launched 15 products during the quarter including 5 injectables.

Europe Formulations

- Europe revenue in Q1 FY24 increased by 18.6% YoY at INR 1,837 Cr. Europe Formulations accounted for 26.8% of consolidated revenue. In Euro terms, Europe revenue increased by 8.8% YoY to EUR 205.4 million.

ARV Formulations

- ARV business revenue for Q1 FY24 stood at INR 190 Cr, accounting for 2.8% of total revenue.

Growth Markets Formulations

- Revenue from Growth Markets formulations in Q1 FY24 posted a growth of 12.9% YoY to INR 486 Cr and accounted for 7.1% of revenue. Domestic formulation sales in Q1 FY24 was INR 52.4 Cr.

Active Pharmaceutical Ingredients (API)

- In Q1 FY24, API business stood at INR 1,033 Cr, increased by 14.0% YoY and contributed 15.1% to the consolidated revenue.

Global Regulatory Filings

Details	Q1FY24	Cumulative Filings as on 30 th June 2023
ANDAs (including filings from Aurobindo USA)	12	814
DMFs (including filings from Eugia and Auro Peptides)	-	276
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	12	4,443
API filings in other key regulated markets (incl. multiple registrations)	-	3,730

Final USFDA Approvals Received in Q1 FY24

#	Product	Therapy
1	Apixaban Tablets, 2.5 mg and 5 mg	Cardiovascular
2	Alcaftadine Ophthalmic Solution, 0.3%	Anti Histamine
3	Macitentan Tablets, 10 mg	Cardiovascular
4	Methylprednisolone Acetate Injectable Suspension USP, 400 mg/10 mL & 400 mg/5 mL	Anti Inflammatory
5	Nitrofurantoin Oral Suspension USP, 25mg/5 mL	Anti Infective
6	Omeprazole Delayed-Release Capsules (OTC), 20 mg	Gastrointestinal
7	Roflumilast Tablets, 500 mcg	Anti Inflammatory
8	Fexofenadine Hydrochloride Oral Suspension (OTC), 30 mg/5 mL	Anti Histamine
9	Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL) [Multiple-Dose Vial]	Anti Neoplastic
10	Estradiol and Norethindrone Acetate Tablets USP, 1 mg/0.5 mg and 0.5 mg/0.1 mg	Hormonal
11	Cevimeline Hydrochloride Capsules, 30 mg	Prosecretory (Cholinergic Agonist)
12	Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) [Single-Dose Prefilled Syringe]	Antiestrogen
13	Phenoxybenzamine Hydrochloride Capsules USP, 10 mg	Cardiovascular
14	Safinamide Tablets, 50 mg and 100 mg	Central Nervous System
15	Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 mcg/mL) [Single-Dose Flexible Container]	Antiplatelet
16	Carboprost Tromethamine Injection USP, 250 mcg/mL [Single-Dose Vial]	Oxytocic Agent
17	Rufinamide Tablets USP, 200 mg and 400 mg	Central Nervous System
18	Tobramycin for Injection USP, 1.2 g/Vial [Pharmacy Bulk Package]	Aminoglycoside Antibacterial
19	Posaconazole Injection, 300 mg/16.7 mL (18 mg/mL), Single-Dose Vial	Anti Fungal

Q1FY24 Earnings Call Details

The company will host an earnings call at **8.30 AM IST on 14th August 2023**, to discuss the performance and answer any questions from participants.

To join the call through Zoom:

Please pre-register by clicking here: <https://bit.ly/3qiErAV>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) headquartered at Hyderabad, India, develops, manufactures, and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up. The Company is marketing these products globally in over 150 countries.

For Further Information, please contact:

Investor Relations | Corporate Communications

Phone: 040-66725401 / 66725000

Email: ir@aurobindo.com